Radhakrishna Uppala, Radhakrishnan Rupa, Uppala Lavanya V, Trivedi Tithi S, Prajapati Jignesh, Rawal Rakesh M, Muvvala Srinivas B, Bahado-Singh Ray O, Sadhasivam Senthilkumar
Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
Department of Obstetrics and Gynecology, Corewell Health William Beaumont University Hospital, Royal Oak, MI, United States.
Front Pain Res (Lausanne). 2025 Apr 17;6:1497801. doi: 10.3389/fpain.2025.1497801. eCollection 2025.
Opioids are often prescribed for pain relief, yet they pose risks such as addiction, dependence, and overdose. Pregnant women have unique vulnerabilities to opioids and infants born to opioid-exposed mothers could develop neonatal opioid withdrawal syndrome (NOWS). The study of opioid-induced epigenetic changes in chronic pain is in its early stages. This study aimed to identify epigenetic changes in genes associated with chronic pain resulting from maternal opioid exposure during pregnancy.
We analyzed DNA methylation of chronic pain-related genes in 96 placental tissues using Illumina Infinium Methylation EPIC BeadChips. These samples comprised 32 from mothers with infants prenatally exposed to opioids who needed pharmacologic NOWS management (+Opioids/+NOWS), 32 from mothers with prenatally opioid-exposed infants not needing NOWS pharmacologic treatment (+Opioids/-NOWS), and 32 from unexposed control subjects (-Opioids/-NOWS).
The study identified significant methylation changes at 111 CpG sites in pain-related genes among opioid-exposed infants, with 54 CpGs hypomethylated and 57 hypermethylated. These genes play a crucial role in various biological processes, including telomere length regulation (); inflammation (); glucose metabolism (); ion channel function (); autophagy (); oxidative stress (); aging (); cytokine activity (); and the risk of suicide (). These epigenetic changes may influence 48 signaling pathways-including cAMP, MAPK, GnRH secretion, estrogen signaling, morphine addiction, circadian rhythms, and insulin secretion-profoundly affecting pain and inflammation-related processes.
The identified methylation alterations may shed light on pain, neurodevelopmental changes, and other biological mechanisms in opioid-exposed infants and mothers with OUD, offering insights into NOWS and maternal-infant health. These findings may also pave the way for targeted interventions and improved pain management, highlighting the potential for integrated care strategies to address the interconnected health of mothers and infants.
阿片类药物常用于缓解疼痛,但它们存在成瘾、依赖和过量使用等风险。孕妇对阿片类药物有独特的易感性,阿片类药物暴露母亲所生的婴儿可能会患上新生儿阿片类药物戒断综合征(NOWS)。阿片类药物诱导的慢性疼痛表观遗传变化的研究尚处于早期阶段。本研究旨在确定孕期母亲阿片类药物暴露导致的与慢性疼痛相关基因的表观遗传变化。
我们使用Illumina Infinium甲基化EPIC芯片分析了96份胎盘组织中慢性疼痛相关基因的DNA甲基化情况。这些样本包括32份来自产前暴露于阿片类药物且其婴儿需要NOWS药物治疗的母亲(+阿片类药物/+NOWS),32份来自产前暴露于阿片类药物但其婴儿不需要NOWS药物治疗的母亲(+阿片类药物/-NOWS),以及32份来自未暴露的对照受试者(-阿片类药物/-NOWS)。
该研究在阿片类药物暴露婴儿的疼痛相关基因中鉴定出111个CpG位点存在显著的甲基化变化,其中54个CpG位点低甲基化,57个高甲基化。这些基因在各种生物学过程中发挥关键作用,包括端粒长度调节();炎症();葡萄糖代谢();离子通道功能();自噬();氧化应激();衰老();细胞因子活性();以及自杀风险()。这些表观遗传变化可能会深刻影响48条信号通路,包括cAMP、MAPK、GnRH分泌、雌激素信号传导、吗啡成瘾、昼夜节律和胰岛素分泌,从而对疼痛和炎症相关过程产生重大影响。
所确定的甲基化改变可能有助于揭示阿片类药物暴露婴儿和患有阿片类药物使用障碍的母亲的疼痛、神经发育变化及其他生物学机制,为NOWS和母婴健康提供见解。这些发现也可能为有针对性的干预措施和改善疼痛管理铺平道路,凸显了综合护理策略在解决母婴相互关联健康问题方面的潜力。